Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Polycystic Ovary Syndrome 1Lymphoma, Follicular 1Diabetes Mellitus, Type 2 1Dementia 1Cognitive Dysfunction 1

Interventions

Rituximab 295Cyclophosphamide 240Peripheral Blood Stem Cell Transplantation 114fludarabine phosphate 110Filgrastim 93Etoposide 85Radiotherapy 81Lenalidomide 79Vincristine 78Prednisone 77Mycophenolic Acid 66Doxorubicin 61Cyclosporine 59Whole-Body Irradiation 58Bendamustine Hydrochloride 58Melphalan 57Tacrolimus 53Busulfan 51fludarabine 50Cytarabine 48obinutuzumab 46Methotrexate 45Antilymphocyte Serum 43Bortezomib 42Methylprednisolone 37Carmustine 37sargramostim 36ibritumomab tiuxetan 32ibrutinib 30Dexamethasone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphoma, Follicular × mazdutide × Clear all
NCT07083154 2026-03-05

GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 3 Recruiting
420 enrolled
Lymphoid

Dementia, Diabetes Mellitus, Type 2, Lymphoma, Follicular, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡